Should you buy Biomea Fusion stock now?
No, the technical signal for Biomea Fusion is currently SELL. Biomea Fusion trades at $1.29 as of 8/6/2026. The overall technical signal is: Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.025 with falling momentum (signal: -0.022); RSI is at 48.8 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $6.83 points to 429.5% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Biomea Fusion stock?
The average analyst price target for Biomea Fusion is $6.83. The current price is $1.29, which gives an upside of 429.5%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $6.15 and $7.51.
Is Biomea Fusion a dividend stock?
No, Biomea Fusion does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Biomea Fusion stock?
Biomea Fusion is rated as a stock with extreme risk. the annual standard deviation is 88.9%, which classifies the stock as extreme risk.
Is Biomea Fusion overvalued?
No, Biomea Fusion is considered undervalued based on the analyst price target (429.5% upside). Biomea Fusion has the following valuation ratios: a P/B ratio of 4.5. The analyst price target suggests that the stock is undervalued by 429.5%.
Is Biomea Fusion overbought?
No, Biomea Fusion is not overbought. RSI is at 48.8 (neutral zone). The technical indicators show: RSI is at 48.8 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 1.8% above the 20-day average (short-term uptrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Biomea Fusion earnings report?
The date of the next earnings report for Biomea Fusion has not been published yet. Check the company's investor calendar for updates.
Is Biomea Fusion shorted?
Yes, Biomea Fusion is shorted with 17.6% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Biomea Fusion stock?
No, insiders are not buying Biomea Fusion shares – they are net sellers. Across the last 20 reported transactions, the split is 14 purchases and 6 sales, with a net 12,717,621 $ sold. Active sellers include A2A Pharmaceuticals, Inc., A2a Pharmaceuticals, Inc.. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Biomea Fusion a good stock?
Based on our total score, Biomea Fusion is rated as a disastrous stock with a total score of 9 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 9/100, Quality: 6/100, Momentum: 13/100. In addition: analysts see 429.5% upside to the price target; technical signal: Sell. Whether Biomea Fusion is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Biomea Fusion stock?
The outlook for Biomea Fusion based on current data: the average analyst price target is $6.83 (+429.5%). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Biomea Fusion stock moving?
Biomea Fusion is stable right now. The technical indicators show: the price is close to the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 17.6% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Biomea Fusion go?
The average analyst price target for Biomea Fusion is $6.83, which corresponds to a potential gain of 429.5% from the current price of $1.29. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Biomea Fusion fall?
We lack enough history to give a specific floor for Biomea Fusion. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Biomea Fusion do?
Biomea Fusion, Inc. er et biotekselskab, der arbejder med at finde og udvikle nye lægemidler. De fokuserer især på små, kovalente molekyler, som skal behandle patienter med genetisk bestemte kræftformer og stofskiftesygdomme.
De udvikler i øjeblikket BMF-219, som er deres vig... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Biomea Fusion as an investment.
Did Biomea Fusion raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Biomea Fusion. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Biomea Fusion making money or losing money?
We have no current profitability data for Biomea Fusion. See the latest report in the earnings history above.
Can Biomea Fusion go bankrupt?
The bankruptcy risk of Biomea Fusion is rated as elevated. Altman Z2 (a model for assessing financial distress) is -33.32 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 55% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Biomea Fusion have a lot of debt?
No, Biomea Fusion has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 55%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
